Patient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy DOI Open Access
Pablo A. Palacios,

Iván Flores,

Lucas Cereceda

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(3), P. 406 - 406

Published: Jan. 26, 2025

Invariant Natural Killer T (iNKT) cells are a unique subset of that bridge innate and adaptive immunity, displaying potent anti-tumor properties through cytokine secretion, direct cytotoxicity, recruitment immune effector such as CD8+ NK cells. Despite their therapeutic potential, the immunosuppressive tumor microenvironment (TME), characterized by regulatory cells, myeloid-derived suppressor (MDSCs), tumor-associated macrophages (TAMs), limits iNKT cell efficacy. Patient-derived organoid (PDO) platforms provide an innovative model for dissecting these complex interactions evaluating strategies to reinvigorate functionality within TME. PDOs closely mimic genetic, phenotypic, structural characteristics primary tumors, enabling study tumor–immune dynamics. Integrating into offers robust platform investigating CD1d-mediated interactions, Th1-biased responses driven glycolipid analogs like α-GalCer, combination therapies checkpoint inhibitors. Additionally, PDO systems can assess effects metabolic modulation, including reducing lactic acid accumulation or targeting glutamine pathways, on enhancing activity. Emerging innovations, organoid-on-a-chip systems, CRISPR-Cas9 gene editing, multi-omics approaches, further expand potential PDO–iNKT personalized immunotherapy research. Although application in is still undeveloped, hold immense promise bridging preclinical studies clinical translation. By addressing challenges TME optimizing strategies, offer transformative avenue advancing cancer medicine.

Language: Английский

Patient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy DOI Open Access
Pablo A. Palacios,

Iván Flores,

Lucas Cereceda

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(3), P. 406 - 406

Published: Jan. 26, 2025

Invariant Natural Killer T (iNKT) cells are a unique subset of that bridge innate and adaptive immunity, displaying potent anti-tumor properties through cytokine secretion, direct cytotoxicity, recruitment immune effector such as CD8+ NK cells. Despite their therapeutic potential, the immunosuppressive tumor microenvironment (TME), characterized by regulatory cells, myeloid-derived suppressor (MDSCs), tumor-associated macrophages (TAMs), limits iNKT cell efficacy. Patient-derived organoid (PDO) platforms provide an innovative model for dissecting these complex interactions evaluating strategies to reinvigorate functionality within TME. PDOs closely mimic genetic, phenotypic, structural characteristics primary tumors, enabling study tumor–immune dynamics. Integrating into offers robust platform investigating CD1d-mediated interactions, Th1-biased responses driven glycolipid analogs like α-GalCer, combination therapies checkpoint inhibitors. Additionally, PDO systems can assess effects metabolic modulation, including reducing lactic acid accumulation or targeting glutamine pathways, on enhancing activity. Emerging innovations, organoid-on-a-chip systems, CRISPR-Cas9 gene editing, multi-omics approaches, further expand potential PDO–iNKT personalized immunotherapy research. Although application in is still undeveloped, hold immense promise bridging preclinical studies clinical translation. By addressing challenges TME optimizing strategies, offer transformative avenue advancing cancer medicine.

Language: Английский

Citations

0